Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Medical Device Stocks to Invest In Right Now

In this article, we will look at the 10 Best Medical Device Stocks to Invest In Right Now.

On April 27, Tom Lee, Fundstrat Capital Chief Investment Officer and Bitmine Immersion Technologies Chairman, appeared on CNBC’s ‘Power Lunch’ to discuss the outlook for equity markets. He was of the view that the market at the start of this year had three risks that it had to get comfortable with, with the first being Iran and a potential escalation of the war, the second being private credit, and the third being a new Fed chair. We have seen that we have come out of the other side of the Iran war with the economy showing remarkable strength, with earnings estimates going up.

READ ALSO: 8 Best Low Volatility Stocks to Invest In Right Now AND 10 Cheap Stocks to Buy Under $20

The underwriting for the private credit looks better than expected, which is why IGV, the software ETF, is rebounding: it fell all the way down to 72 and is back to 85. A lot of private credit loans were tied to software, and according to him, that is less of a structural problem. Lee further believes that for stocks, the upside case is strengthening for the year, with the S&P above 7,700 being very probable.

With these broader market trends in view, let’s narrow down and look at the best medical device stocks to invest in right now.

Our Methodology

We used the Finviz stock screener to make a list of the best medical device stocks and picked the top 10 with the highest number of hedge fund holders, as of Q4 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database.

Note: All data was recorded on April 28.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Medical Device Stocks to Invest In Right Now

10. Smith & Nephew plc (NYSE:SNN)

Smith & Nephew plc (NYSE:SNN) is one of the best medical device stocks to invest in right now. Canaccord cut the price target on Smith & Nephew plc (NYSE:SNN) to $32 from $35 on April 24 and reaffirmed a Hold rating on the shares. The firm updated its model ahead of the fiscal Q1 results.

In a separate development, Smith & Nephew plc (NYSE:SNN) announced on April 21 compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant. Recently published in the American Journal of Sports Medicine, the CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores compared to surgical standard of care for all time points out to 60 months.

Smith & Nephew plc (NYSE:SNN) reported that patients treated with the CARTIHEAL AGILI-C Implant reported considerably better knee pain relief, along with improvements in quality of life over a 5-year period. In addition, patients “treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport, and recreation at 2, 4, and 5-years”.

Smith & Nephew plc (NYSE:SNN) develops, manufactures, markets, and sells medical devices. Its operations are divided into the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management.

9. iRhythm Technologies, Inc. (NASDAQ:IRTC)

iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the best medical device stocks to invest in right now. Truist cut the price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $170 from $200 on April 15, reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm telling investors in the research note that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated that the stock should trade at least in line with, if not higher than, its peer group average, given the upward bias to consensus revenue growth forecasts into the out- years as well as the company’s re-accelerating revenue growth potential in 2027, which could materialize upon MCT, Mobile Cardiac Telemetry service, approval.

iRhythm Technologies, Inc. (NASDAQ:IRTC) also received a rating update from BTIG on April 13. The firm cut the price target on the stock to $185 from $215 and maintained a Buy rating on the shares. The rating update came as part of a broader research name on Medical Technology.

iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company that provides design, development, and commercialization of device-based technology. It provides ambulatory cardiac monitoring services, along with solutions to detect, predict, and prevent disease.

8. GE HealthCare Technologies Inc. (NASDAQ:GEHC)

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best medical device stocks to invest in right now. Piper Sandler cut the price target on GE HealthCare Technologies Inc. (NASDAQ:GEHC) to $88 from $96 on April 17, reaffirming an Overweight rating on the shares. The firm stated that it is adding the recent acquisition of Intelerad into its model, and that this is inclusive of an additional $270M in annual revenue, a $75M increase in annual adjusted EBIT, and EPS that is slightly dilutive in 2026 and accretive in 2027 and 2028.

In a separate development, GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced on April 23 that the first patient had been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. If approved, Mangaciclanol could offer an alternative to, or even potentially replace, gadolinium-based MRI contrast agents, which are the current standard of care.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) further reported that the investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) develops and manufactures medical technology, pharmaceutical diagnostics, and digital solutions. The company’s operations are divided into the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

7. Insulet Corporation (NASDAQ:PODD)

Insulet Corporation (NASDAQ:PODD) is one of the best medical device stocks to invest in right now. On April 24, Insulet Corporation (NASDAQ:PODD) was downgraded to Neutral from Buy by Rothschild & Co Redburn, with the firm bringing the price target on the stock down to $220 from $380. It told investors in a research note that the company’s distribution and product moats are “eroding”, and it believes that the company’s “elevated expectations” leave the stock’s risk/reward skewed to the downside. The firm contended that Insulet Corporation’s (NASDAQ:PODD) slowing growth profile challenges its ability to sustain its premium multiple relative to the sector.

Insulet Corporation (NASDAQ:PODD) also received a rating update from Truist on April 15. The firm cut the price target on the stock to $315 from $360 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in the MedTech sector. Truist told investors in the research note that the firm anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around the fiscal Q1 volumes.

Insulet Corporation (NASDAQ:PODD) is a medical device company that develops, markets, and manufactures an insulin infusion system for people with insulin-dependent diabetes. The company specializes in diabetes supplies, along with other diabetes related products and supplies, including pump supplies, traditional insulin pumps, blood glucose testing supplies, and pharmaceuticals.

6. Medtronic plc (NYSE:MDT)

Medtronic plc (NYSE:MDT) is one of the best medical device stocks to invest in right now. Medtronic plc (NYSE:MDT) announced on April 28 that it received the CE mark for the Stealth AXiS™ surgical system, indicated for spine and cranial procedures. Management stated that the system is a next-generation platform that amalgamates navigation, planning, and robotics into a single intelligent system and is scalable across multiple surgical specialties for the company.

In a separate development, Medtronic plc (NYSE:MDT) announced on April 25 continued momentum for the Affera™ family of technologies for cardiac arrhythmia treatment. This includes promising data presented at the Heart Rhythm Society (HRS) Annual Meeting as well as the start of a new trial evaluating a broader population of atrial fibrillation (AFib) patients.

The company further stated that with global commercial expansion and ongoing positive physician feedback, Medtronic plc (NYSE:MDT) is continually investing in clinical research to study the Affera mapping and ablation system for potential new indications. It added that results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9™ catheter for treatment of recurrent sustained monomorphic ventricular tachycardia after a heart attack showed that 65.5% of patients remained free from VT recurrence at six months.

Medtronic plc (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies. It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

While we acknowledge the potential of MDT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDT and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Best Medical Device Stocks to Invest In Right Now.

Disclosure: None. Follow Insider Monkey on Google News.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.